Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors. 

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors. 

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors 

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

A new drug application has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer.

FDA Approval Sought for Sunvozertinib in Pretreated EGFR Exon 20+ Advanced NSCLC

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Applications have been submitted to the FDA and EMA seeking approval for daratumumab in high-risk smoldering multiple myeloma.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

Fox Chase Cancer Center is pleased to announce the hiring of Lorenzo Galluzzi, PhD, as an Associate Professor with tenure in the Cancer Signaling and Microenvironment Research Program.  

Fox Chase Cancer Center Welcomes Lorenzo Galluzzi

A phase 1 trial is examining the use of mesenchymal stromal cells for treatment of radiation-induced xerostomia in patients who have completed radiation.

Partner Perspectives: Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

My Treatment Approach: Graft vs Host Disease

Videos

Nelson J. Chao, MD, MBA, discusses the treatment of acute and chronic graft-versus-host disease through the lens of two patient profiles.

Nelson J. Chao, MD, MBA, presents the patient profile of a 60-year-old man with chronic myeloid leukemia and graft-versus-host disease (GVHD) and shares his initial impressions.

Patient Profile Presentation: A 60-Year-Old Man with Graft-Versus-Host Disease (GVHD)				

Dr Nelson J. Chao reviews how chronic graft-versus-host disease is diagnosed and staged, and the importance of multidisciplinary team communication.

Staging of Chronic GVHD

Nelson J. Chao, MD, MBA, explains the frontline treatment options for chronic GVHD, and when to consider restarting an immunosuppressive regimen.

First-Line Treatment Options for Patients with Chronic GVHD

Dr Nelson J. Chao presents the patient profile of a 67-year-old woman with chronic graft-versus-host disease after a bone marrow donation from a multiparous female.

Patient Profile Presentation: A 67-Year-Old Woman with GVHD

Nelson J. Chao, MD, MBA, details some novel agents being developed for the systemic treatment of GVHD, particularly chronic GVHD.

Investigational Systemic Treatment Options for GVHD

Dr Nelson J. Chao reviews treatment sequencing and speculates on the future of the GVHD treatment landscape.

Treatment Sequencing and Future of GVHD

Pashna Munshi, MD, presents the patient profile of a 44-year-old woman with acute myeloid leukemia diagnosed with grade 2 skin acute GVHD, and shares her initial impressions and what she might have done differently.

Patient Profile Presentation: A 44-Year-Old Woman With Acute Myeloid Leukemia and Graft-Versus-Host Disease (GVHD)

Dr Pashna Munshi describes for what myeloid malignancies allogeneic transplantation is indicated, and its curative potential.

Indications for Allogeneic Stem Cell Transplantation in the Treatment of Myeloid Malignancies

Pashna Munshi, MD, details how age and risk factors into her choice of conditioning regimen for patients with GVHD receiving allogeneic transplant.

Tailored Conditioning Regimens for Patients with GVHD Receiving Allogeneic Transplant

Dr Pashna Munshi explains the currently available options for GVHD prophylaxis and which regimens she utilizes the most in her clinical practice.

Currently Available Options for GVHD Prophylaxis

Pashna Munshi, MD, reviews the differences between acute and chronic GVHD.

Comparing Acute and Chronic GVHD

Pashna Munshi, MD, discusses how acute GVHD is staged and graded, and the common frontline treatment options.

Available Frontline Treatment Options for Patients With Acute GVHD

Closing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.

Current Treatment Options for Patients with Steroid-Refractory Acute GVHD

Insights Video Series

Tailored Conditioning Regimens for Patients with GVHD Receiving Allogeneic Transplant

EP: 1.Patient Profile Presentation: A 60-Year-Old Man with Graft-Versus-Host Disease (GVHD)

EP: 2.Staging of Chronic GVHD

EP: 3.First-Line Treatment Options for Patients with Chronic GVHD

EP: 4.Patient Profile Presentation: A 67-Year-Old Woman with GVHD

EP: 5.Investigational Systemic Treatment Options for GVHD

EP: 6.Treatment Sequencing and Future of GVHD

EP: 7.Patient Profile Presentation: A 44-Year-Old Woman With Acute Myeloid Leukemia and Graft-Versus-Host Disease (GVHD)

EP: 8.Indications for Allogeneic Stem Cell Transplantation in the Treatment of Myeloid Malignancies

EP: 9.Tailored Conditioning Regimens for Patients with GVHD Receiving Allogeneic Transplant

EP: 10.Currently Available Options for GVHD Prophylaxis

EP: 11.Comparing Acute and Chronic GVHD

EP: 12.Available Frontline Treatment Options for Patients With Acute GVHD

EP: 13.Current Treatment Options for Patients with Steroid-Refractory Acute GVHD

Latest Conference Coverage